Recommendations for Use of Marginal Donors in Heart Transplantation: Brazilian Association of Organs Transplantation Guideline
Carregando...
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
CONTRERAS, C. A. M.
DINKHUYSEN, J. J.
MOREIRA, M. C. V.
MEJIA, J. A. C.
Citação
TRANSPLANTATION PROCEEDINGS, v.43, n.1, p.211-215, 2011
Resumo
The high prevalence of heart failure has increased the candidate list for heart transplantation; however, there is a shortage of viable donated organs, which is responsible for the high mortality of patients a waiting a transplantation. Because the marginal donor presents additional risk factors, it is not considered to be an ideal donor. The use of a marginal donor is only justified in situations when the risk of patient death due to heart disease is greater than that offered by the donor. These recommendations sought to expand the supply of donors, consequently increasing the transplant rate. We selected articles based on robust evidence to provide a substratum to develop recommendations for donors who exceed the traditional acceptance criteria. Recipient survival in the immediate postoperative period is intimately linked to allograft quality. Primary allograft failure is responsible for 38% to 40% of immediate deaths after heart transplantation: therefore; marginal donor selection must be more rigorous to not increase the surgical risk. The main donor risk factors with the respective evidence levels are: cancer in the donor (B), female donor (B), donor death due to hemorrhagic stroke (B), donor age above 50 years (relative risk [RR] = 1.5) (B), weight mismatch between donor and recipient < 0.8 (RR = 1.3) (B), ischemia > 240 minutes (RR = 1.2) (B), left ventricular dysfunction with ejection fraction below 45% (B), and use of high doses of vasoactive drugs (dopamine > 15 mg/kg . mm) (B). Factors that impact recipient mortality are: age over 50 years (RR = 1.5); allograft harvest at a distance; adult recipient weighing more than 20% of the donor; high doses of vasoactive drugs (dopamine greater than 15 mg/kg . min) and ischemic time >4 hours. The use of a marginal donor is only justified when it is able to increase life expectancy compared with clinical treatment, albeit the outcomes are interior to those using an ideal donor.
Palavras-chave
Referências
- Nagji AS, 2010, ANN THORAC SURG, V90, P168, DOI 10.1016/j.athoracsur.2010.03.043
- Wood KE, 2004, NEW ENGL J MED, V351, P2730, DOI 10.1056/NEJMra013103
- Ali A, 2009, J HEART LUNG TRANSPL, V28, P290, DOI 10.1016/j.healun.2008.12.014
- Gasink LB, 2006, JAMA-J AM MED ASSOC, V296, P1843, DOI 10.1001/jama.296.15.1843
- Bruzzone P, 2008, TRANSPL P, V40, P1064, DOI 10.1016/j.transproceed.2008.03.049
- Mancini D, 2010, CIRCULATION, V122, P173, DOI 10.1161/CIRCULATIONAHA.109.858076
- Chen JM, 2002, J HEART LUNG TRANSPL, V21, P608, DOI 10.1016/S1053-2498(01)00367-9
- Weiss ES, 2009, CIRC-HEART FAIL, V2, P401, DOI 10.1161/CIRCHEARTFAILURE.108.844183
- Lietz K, 2004, J AM COLL CARDIOL, V43, P1553, DOI 10.1016/j.jacc.2004.02.002
- Felker GM, 2005, J HEART LUNG TRANSPL, V24, P1781, DOI 10.1016/j.healun.2005.03.014
- Stehlik J, 2010, J HEART LUNG TRANSPL, V29, P1089, DOI 10.1016/j.healun.2010.08.007
- Xu DS, 2010, TRANSPLANTATION, V89, P873, DOI 10.1097/TP.0b013e3181ca56e0
- Freeman RB, 1999, TRANSPLANTATION, V68, P1107, DOI 10.1097/00007890-199910270-00008
- West LJ, 2006, J THORAC CARDIOV SUR, V131, P455, DOI 10.1016/j.jtcvs.2005.09.048
- BYRNE P, 2005, PAEDIAT CHILD HLTH, V10, P335
- CHAN BBK, 1991, ANN THORAC SURG, V52, P1230
- Chen JM, 2005, ANN THORAC SURG, V80, P224, DOI 10.1016/j.athoracsur.2005.01.022
- FUKUSHIMA N, 1994, J THORAC CARDIOV SUR, V107, P985
- HOUYEL L, 1992, J HEART LUNG TRANSPL, V11, P1184
- Jeevanandam V, 1996, ANN THORAC SURG, V62, P1268, DOI 10.1016/0003-4975(96)00626-1
- Kirk R, 2010, J HEART LUNG TRANSPL, V29, P1119, DOI 10.1016/j.healun.2010.08.009
- Lima B, 2006, CIRCULATION, V114, pI27, DOI 10.1161/CIRCULATIONAHA.105.000737
- Massimelli M, 2007, PANMINERVA MED, V49, P83
- Morath C, 2005, TRANSPLANTATION, V80, pS164, DOI 10.1097/01.tp.0000186911.54901.21
- Sarmento A, 2000, TRANSPLANT P, V32, P2571, DOI 10.1016/S0041-1345(00)01793-0
- SCHULER S, 1988, J HEART TRANSPLANT, V7, P326
- Singhal AK, 2009, TRANSPL P, V41, P3539, DOI 10.1016/j.transproceed.2009.06.192
- Tamisier D, 1996, J HEART LUNG TRANSPL, V15, P190
- Venettoni Sante, 2007, Ann Ist Super Sanita, V43, P279
- 2010, FEDERAL OFFICIA 0606, P85